Herbalife (HLF) Q3 2026 earnings review
Herbalife cuts interest costs, but its chief executive steps down
Herbalife's nutrition business grew fast in Asia while shrinking across the rest of the world, and its chief executive unexpectedly stepped down. Worldwide sales rose 6% to $1.35 billion, and lower interest bills after an April debt refinancing lifted profit per share excluding one-offs by 28%. Outgoing finance chief John DeSimone stepped in as interim chief executive for Stephan Gratziani and raised the full-year sales outlook, though the fourth-quarter plan slows revenue growth to about 3%.
| Worldwide net sales | $1.35B +6.0% from a year ago (+7.6% in local currency) |
|---|---|
| Sales outside Asia Pacific | $832.3M -0.5% from a year ago by our math |
| Profit per share, excluding one-offs | $0.64 +28% from a year ago |
| Full-year outlook | Sales raised EBITDA held at $670–690M; CEO replaced |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because faster debt reduction and lower interest costs are offset by the sudden loss of the chief executive who built the company's new product strategy. Strong cash generation cut net debt to 2.0 times profit, and the board approved a $250 million share buyback. The bad news: sales outside Asia Pacific fell by our math, the release gave zero figures on the new digital platforms, and holding the full-year profit plan after a third-quarter beat cuts fourth-quarter operating profit below what the prior plan pointed to.
The question now is whether Herbalife can still grow once India finishes lapping last September's consumption-tax cut, and whether interim chief executive DeSimone will keep funding Gratziani's personalized-nutrition apps. Either lower prices have permanently expanded Asia Pacific demand, or the tax cut was a one-time boost masking declines in Europe and China. Fourth-quarter Asia Pacific sales and the new leadership's 2027 plan will settle it.
🐂 Bull Case
Refinancing Cuts Interest Costs and Drops Debt Leverage
Herbalife has spent two years paying down debt and refinancing expensive loans to rebuild its balance sheet, while critics worried that a $2.04 billion debt load and a year-end leverage target below 2.0 times would strain cash flow. Finance chief Scott Schaefer said: "Our April refinancing reduced net interest expense by $19.1 million year-over-year in the third quarter, strengthening our earnings and cash generation."
That interest saving cut net interest expense by 1.6 percentage points of sales to $31.9 million, helping the nutrition seller generate $132.8 million of free cash flow in the quarter by our math. The company used that cash to cut total debt under its credit agreement by $87.7 million from last quarter to $1.95 billion, and net debt by $126.4 million to $1.54 billion.
This matters because the cash sweep dropped the net leverage ratio — net debt divided by trailing twelve-month credit-agreement profit — from 2.2 times in June to 2.0 times in September. Herbalife now sits right on the doorstep of its year-end goal with one quarter still to go.
What to watch: fourth-quarter debt repayments against fourth-quarter share buybacks in the full-year report. A net leverage reading below 2.0 times would confirm that the company can fund its new buyback without slowing its plan to reach $1.4 billion of total debt by 2028.
Lower Overhead and Commission Ratios Lift Operating Margin
Herbalife's operating profitability bounced back in the third quarter after dipping in the spring. Profit before interest, taxes, depreciation and one-offs (adjusted EBITDA) rose 11.9% from a year ago to $182.4 million, beating the top of the company's $160 million to $180 million plan. That lifted the adjusted EBITDA margin by 0.7 percentage points to 13.5% of sales, while GAAP operating margin rose 0.4 percentage points to 10.3%.
Two operating cost lines drove the gain as revenue grew 6.0%. General and administrative expenses — corporate overhead and staff costs — fell by 0.4 percentage points of revenue to 32.0%, even with $5.6 million of charges for the Optimization Program, a restructuring plan to consolidate back-office work. Selling expenses, which combine distributor commissions and Chinese service fees, fell by 0.3 percentage points of revenue to 35.1%.
What to watch: fourth-quarter adjusted EBITDA against the $145 million to $165 million outlook. The middle of that range points to an 11.8% margin by our math, down from 12.2% a year ago, which will show whether third-quarter cost savings were just timing.
🐻 Bear Case
Sales Outside Asia Pacific Shrink as Tax Tailwind Laps
Herbalife highlighted a fifth straight quarter of revenue growth as worldwide net sales rose 6.0% to $1.35 billion, or 7.6% in local currency, while supporters point to India's boom after a September 2025 consumption-tax cut as proof that lower prices unlock demand. Beneath the headline, Asia Pacific accounted for more than all of the company's growth, while the rest of the world shrank.
- Asia Pacific net sales: $517.9 million, up $80.5 million or 18.4% from a year ago (26.1% in local currency)
- Net sales outside Asia Pacific: $832.3 million, down $4.0 million or 0.5% from a year ago by our math
- China net sales: $55.6 million, down 22.0% reported and 26.4% in local currency
- EMEA (Europe, the Middle East and Africa) net sales: $259.0 million, down 4.9% reported and 5.2% in local currency
Latin America grew 9.0% on currency tailwinds (5.1% in local currency) and North America edged up 1.7%, but they could not offset drops in Europe and China. Because India's tax cut took effect on September 22, 2025, the fourth quarter is the first full period without that price step-down, and management's fourth-quarter outlook slows worldwide growth to 2.5% at the middle of the range.
What to watch: India's standalone net sales in the quarterly filing and Asia Pacific growth in the fourth quarter. A sharp slowdown in Asia Pacific would leave consolidated sales dependent on regions that are currently shrinking.
CEO Exit and Digital Silence Leave Strategy Unproven
Chief executive Stephan Gratziani spent the past eighteen months pitching a shift from basic protein shakes to personalized wellness, buying software app Pro2col, custom supplement maker Bioniq, and ketone seller Pruvit. On November 1, Gratziani left the chief executive role after less than two years, and retiring finance chief John DeSimone stepped in as interim chief executive while the board searches for a successor.
In the release, DeSimone did not name Pro2col, Bioniq, or the new Life I/O product line that Gratziani had promised to give figures on this quarter. Instead, DeSimone said his priorities include "a focused roadmap for our business opportunity and digital platforms with measurable success metrics" — language that points to a review of the digital rollout rather than a commercial ramp.
Meanwhile, the bill for software keeps arriving. Herbalife spent $14.5 million on capitalized and prepaid cloud-software implementation costs in the third quarter, up from $8.0 million in the second quarter, bringing nine-month spending to $32.5 million on top of $10.0 million in acquisition cash payments.
What to watch: whether DeSimone provides subscriber counts or revenue for Pro2col, Bioniq GO and Life I/O on the conference call. Continued silence after a chief executive change would signal that the acquired platforms are not yet generating material sales.
Manufacturing Costs and Regional Mix Cut Gross Margin
While overhead discipline helped the bottom line, making and shipping the products got more expensive. Gross profit margin slipped 0.4 percentage points from a year ago to 77.3%, down from 77.9% in the first quarter and 77.7% in the second quarter. Cost of sales rose 7.7% to $306.1 million, outpacing the 6.0% revenue gain and taking an extra 0.4 percentage points of sales.
Herbalife said gross margin was "primarily impacted by sales mix pressure and cost changes related to self-manufacturing and sourcing, partially offset by pricing benefits." Fast growth in Asia Pacific, where India carries lower gross margins and an unfavorable consumption-tax credit rule, continues to dilute the company's blended product margin despite price increases.
What to watch: fourth-quarter gross margin once India's tax-cut surge laps. If gross margin keeps falling even as Asia Pacific's share of growth moderates, raw material and factory costs are overriding price increases.
👓 Other Themes
Board Approves $250M Buyback Despite $1.95B Debt Load
In September, Herbalife's board authorized a share repurchase program of up to $250 million over three years, to be executed "systematically and opportunistically beginning in the fourth quarter." The company bought no shares in the third quarter. Finance chief Scott Schaefer said the April refinancing supports a "disciplined and balanced approach to capital allocation, including continued debt reduction and the flexibility to return capital to shareholders through share repurchases."
💲 Other KPIs
Money owed by distributors and customers rose 19.5% from $97.8 million a year ago and 27.2% from $91.9 million at year-end, far outpacing the 6.0% rise in net sales. The buildup absorbed $24.2 million of operating cash flow over the first nine months, similar to the $25.6 million outflow a year earlier.
Diluted shares rose 3.2% from 104.0 million a year ago and 2.7% from 104.5 million in the second quarter. Stock-based compensation and dilutive securities have steadily expanded the share count over the past year, creating a drag on per-share profit that the new fourth-quarter buyback program aims to counter.
By our math, total cash spent on property, equipment and software implementation reached $33.0 million in the quarter, up from $19.3 million in the second quarter and $27.8 million a year ago. Property and equipment purchases were $18.5 million, while capitalized cloud-software implementation costs — which Herbalife excludes from capital expenditures — rose to $14.5 million.
🔮 Guidance
Raised against the prior implied range. The plan calls for 2.5% growth at the middle of the range, or about $1.315 billion, down from 6.0% growth in the third quarter and 2.6% lower than third-quarter sales by our math. In constant currency, the company forecasts 2.5% to 6.5% growth. Growth slows because the fourth quarter laps last year's 6.3% jump and India's September 2025 consumption-tax cut.
Cut against what the prior full-year plan implied. The middle of the range is $155 million, down 0.7% from $156.1 million a year ago and down 15.0% from the third quarter by our math, vs the $167.7 million previously implied by the full-year outlook. Constant-currency adjusted EBITDA is planned at $155 million to $175 million. The third-quarter beat was absorbed by a lower fourth-quarter forecast.
Raised. The middle of the range moved up 1.4 percentage points to 5.4% growth (5.3% to 6.3% in constant currency, up from 2.5% to 5.5%). Across four quarters, the reported growth midpoint moved by 0.0, +0.5 and +1.4 percentage points. Because Herbalife has beaten its quarterly sales midpoint for four straight quarters by an average of 2.8 points, it would finish near the top of the range if the pattern holds.
Unchanged on a reported basis, and raised by $10 million in constant currency to $700 million to $720 million. The middle of the reported range ($680 million) represents 3.4% growth from $657.6 million in 2025. Even though third-quarter adjusted EBITDA beat the middle of its plan by $12.4 million, currency headwinds and a softer fourth-quarter margin kept the full-year reported dollar target flat.
Tightened and trimmed. Full-year capital expenditures were narrowed to $55 million to $65 million (with $13 million to $23 million in the fourth quarter), while capitalized software implementation costs were trimmed by $5 million at the middle of the range to $35 million to $45 million. Full-year depreciation and software amortization was also lowered by $5 million to $135 million to $145 million, and the adjusted tax rate stays at 35%.
❓ Key Questions
Why did Stephan Gratziani step down as CEO now?
Gratziani took over as chief executive in early 2025 to lead the personalized-nutrition overhaul and left on November 1 without explanation in the release. Investors need to know whether the board disagreed with his acquisition and digital-platform spending.
What are the sales for Life I/O, Pro2col and Bioniq?
Last quarter, Gratziani promised to share figures for the new Life I/O product line on the third-quarter call, but the release mentions none of the new platforms. Without user or revenue numbers, the $32.5 million of year-to-date software spending has no visible payback.
How much did India grow, and what happens in Q4?
In the second quarter, India generated $67.0 million of Herbalife's $67.7 million sales increase. The release gives only the broader Asia Pacific total (+$80.5 million); the quarterly filing must show whether non-India markets are still shrinking as India laps its September 2025 tax cut.
Why does the Q4 outlook cut implied EBITDA by $13M?
Holding full-year adjusted EBITDA at $670 million to $690 million after a $12.4 million third-quarter beat lowers fourth-quarter EBITDA to $155 million at the midpoint, vs $167.7 million implied three months ago. Management has not said whether currency, marketing or factory costs caused the drop.